Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ferring's New Chief Falk Talks

Executive Summary

Ferring announced this morning (Oct. 31) that Michel Pettigrew is retiring as president of the executive board and will be succeeded by CSO Per Falk. The two spoke to Scrip recently and outlined the Swiss-based firm's future strategy.

You may also be interested in...



Ferring Plots Genomics Path With Celmatix Pact

The firms have inked a collaboration which aims to explore individual differences in women’s responses to IVF treatment, improve success rates and reduce side effects such as ovarian hyper-stimulation syndrome.

Ferring Makes Foray Into Gene Therapy With FKD Pact

The Swiss company's CMO Klaus Dugi tells Scrip that getting the rights to a late-stage bladder cancer gene therapy from Finland's FKD highlights the transformation that Ferring is undergoing.

Interview: Ferring Forges Ahead With mAbs For Reproductive Meds

Antibody-based therapies have not really been investigated in the area of reproductive medicine and women’s health but Ferring is investing heavily to explore their potential, head of global pharmaceutical R&D Armin Metzger tells Scrip.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel